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change in MPR observed for patients initiating GXR while on LA stimulants alone 
versus those on SA or SA+LA stimulants.
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Objectives: To describe patients’ characteristics and patterns of use of depot antip-
sychotics in patients with a diagnosis of schizophrenia in Germany. MethOds: 
Claims data were analysed from German patients covered by Elsevier Health Risk 
Research Database between 2009-2011 (approx 7.6 million insured persons). The 
study sample consisted of adult patients who initiated a given depot antipsychotic 
for schizophrenia (F20) or schizoaffective disorder (F25) in 2010. Baseline clinical 
characteristics of patients were searched over the year prior to depot initiation. 
Persistence (treatment duration) with depot treatment was assessed using a 
Kaplan-Meier survival analysis until discontinuation or end of the study period (31 
December 2011). Results: A total of 2,240 patients with a diagnosis of schizophre-
nia or schizoaffective disorder (mean age 50.7 years, 48.8% male) were included. At 
baseline, the main psychiatric comorbidities were major depressive disorder (38% of 
patients), substance use disorders (29%) and anxiety disorders (13%). Main somatic 
conditions were cardiovascular diseases (37%), neurological disorders (33%) and 
hyperlipidemia (27%). Depot antipsychotics prescribed were mainly risperidone 
long acting (32%), flupentixol (31%) and haloperidol decanoate (17%). Prescribers 
were psychiatrists/neurologists (58%), GPs (16%), other/unknown (26%). Median per-
sistence to depot antipsychotic treatment was 156 days. cOnclusiOns: To our 
knowledge, this is the first large database study conducted in Germany aiming at 
describing the patients’ characteristics and treatment patterns of schizophrenic 
patients treated with depot antipsychotics. It is notable that the current sub-popu-
lation of schizophrenic patients treated with depot showed substantial psychiatric 
and cardiovascular co-morbidities.
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Objectives: To visualize heterogeneity in treatment pathways and outcomes 
among children and adolescents with ADHD in Europe. MethOds: Retrospective 
chart review of 779 ADHD patients (aged 6–17 years) diagnosed by 340 clinicians 
between 2004 and 2007 in six European countries. Receipt of ADHD medication 
and/or behavioural therapy (BT) was evaluated across the study period. Patient 
characteristics, treatment patterns, physician-reported satisfaction and symp-
tom control were analysed in the total population and among patients with at 
least one switch in ADHD therapy during follow-up (switchers). Optimal treatment 
success (OTS) was defined as high satisfaction and complete symptom control 
at chart review. Results: Most patients treated with ADHD medication (89.5%) 
received methylphenidate. Among 386 patients (49.6%) who remained on their 
initial treatment throughout the chart review period, the majority (86.3%) were 
treated with ADHD medication alone or in combination with BT. Switchers (n= 393; 
50.4%) did not differ significantly at baseline from non-switchers. Few patients 
(n= 98; 12.6%) switched more than once. The most common types of switch (first 
and last treatments considered) were from one monotherapy to another (n= 91; 
23.2%) or change of medication co-administered with BT (n= 54; 13.7%). The most 
common reasons for last switch were suboptimal response (40.2%), duration of 
action (18.1%) or both (14.5%). At review, among those who switched, 11.7% discon-
tinued all ADHD treatment and 5.1% received only BT. Overall, OTS was 27.4% with 
no significant difference between switchers and non-switchers (29.1% vs 25.5%; 
p= 0.281). cOnclusiOns: About half the patients switched from their initial treat-
ment during chart review, mostly due to suboptimal response, with many (16.8%) 
discontinuing ADHD medications. Furthermore, OTS remained low regardless of 
whether a patient switched ADHD therapies. Together, these observations suggest 
currently available ADHD treatments are inadequate for achieving OTS among chil-
dren and adolescents in Europe.
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Objectives: To describe patients’ characteristics and patterns of use of depot 
antipsychotics in patients with a diagnosis of schizophrenia in Sweden. MethOds: 
A retrospective analysis was conducted based on longitudinal and population-
based data in the Swedish national health registries. The study sample con-
sisted of adult patients who initiated a treatment with any depot antipsychotic 
for schizophrenia (F20) or schizoaffective disorder (F25) in 2009-2010. Baseline 
clinical characteristics of patients were searched over the year prior to depot 
initiation. Persistence (treatment duration) with depot treatment was assessed 
using a Kaplan-Meier survival analysis until discontinuation or end of the study 
period (31 December 2011). Results: A total of 2,879 patients with a diagno-
sis of schizophrenia or schizoaffective disorder were included. Mean age was 
50.0 years and 54.4% of the patients were male. At baseline, the main psychiatric 
comorbidities were other psychotic disorders (17% of patients), substance use 
disorders (11%) and major depressive disorders (3%). Somatic conditions were 
for dementia patients, caregivers and medical professionals on the basis of a web-
based platform. MethOds: Within the PeKS, involved endusers will be provided 
disease- as well as situation-specific information from existing, evidence-based 
digital information (links, PDFs, videos) but also from local and regional informa-
tion sources. The overall aim is to enable increased knowledge and competence by 
providing situation-specific and on time information. On the other hand, the PeKS 
includes an interactive monitoring tool, thus enhancing (shared) medical decision 
support by connecting patients/caregivers and medical professionals. After the tech-
nical integration of the concept, a running prototype will be available. Results: The 
developed prototype of the ‘Personal eHealth Knowledge Space’ is realized by inte-
grating service-oriented architecture, knowledge engineering, multiagent systems, 
and wearable/portable device technologies. An interactive monitoring tool, based 
on information provided by caregivers will be realized by integrating the ‘Nurses’ 
Observation Scale for Geriatric Patients (NOSGER)’. Individualized information is 
going to be provided through push- and pull mechanisms. cOnclusiOns: Health 
support systems addressing individual dementia patients/caregiver needs have a 
large potential, however they are scarce. eHealthMonitor’s overall objective is to 
significantly increase the individualization of personal eHealth services and thereby 
the quality and patients’ acceptance of electronic health care services for preven-
tion, treatment and care. The research is funded by the European Commission, ICT 
FP7, project ID 287509.
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Objectives: A number of medication surveys conducted in the U.S. have demon-
strated a high level of psychotropic drug use in patients diagnosed with pervasive 
development disorder (PDD). Medication use is of interest as not many products 
are approved for treatment in autism. Describe drug use in subjects newly diag-
nosed with PDD in Quebec province. MethOds: A cohort study was built by using 
Quebec RAMQ and Med-Echo databases for subjects having a new PDD diagnosis 
(ICD-9 codes: 299.0-299.9) between January 1998 and December 2010. Cohort entry 
date was the date of a first diagnosis confirmed by the absence of PDD diagnosis 
in previous 2 years, and aged less than 26 years. Descriptive analyses of patient 
characteristics were done at cohort entry and drug use profiles were done the 
year prior to, and within the 3 years following diagnosis. Results: A cohort of 
4684 subjects was identified; 78% of patients were male and the age ranges were 
as follows: 41.9% (1-5 years), 31.2% (6-12 years), 12.3% (13-17 years), 14.7% (18-
25 years). Prior to being diagnosed with PDD, 35% received at least 1 psychoac-
tive drug. Methylphenidate was most common in 6-12 year olds (36%) whereas 
antipsychotics were most common in the 13-17 group (28.6%) and in the adult 
population (51.7%). Antipsychotic use was also present in younger children: 5.7% 
in 1-5 year olds and 23% in 6-12 year olds, 1 year after diagnosis. Antipsychotic, 
antidepressant and anticonvulsant usage increased in the 3 years following diag-
nosis, and also with age. cOnclusiOns: Prior to PDD diagnosis, more than a third 
of the patients were on psychotropic medications, a practice that continued and 
increased after diagnosis. Psychoactive drug utilization is high and could be of 
concern if used to compensate for limited access to other treatment modalities 
such as educational and allied health therapies.
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Objectives: To assess stimulant adherence among pediatric patients with 
attention-deficit/hyperactivity disorder (ADHD) after adding guanfacine extended-
release (GXR) as adjunctive therapy to stimulants in a US managed care set-
ting. MethOds: Data from the MarketScan Commercial Claims and Encounters 
insurance claims database (2009-2011) were used. Patient inclusion criteria were: 
6-17 years old; ≥ 1 ADHD diagnosis (ICD-9-CM code 314.00 or 314.01); ≥ 1 long-acting 
(LA) and/or short-acting (SA) stimulant prescription; continued stimulant therapy 
for ≥ 30 days and ≥ 6 months of continuous insurance coverage pre- and post-
GXR initiation; and nonadherent to stimulant treatment pre-GXR. Adherence was 
assessed using the medication possession ratio [MPR] (range= 0.0-1.0), with MPR 
< 0.80 considered nonadherent. Change in stimulant adherence pre- to post-GXR 
initiation was assessed using an OLS multivariable model, adjusting for patient 
age, sex, and geographic region; GXR dose (last observed), adherence, dose sta-
bilization, and year of initiation; number of non-ADHD prescriptions pre-GXR; 
stimulant MPR pre-GXR; and stimulant received (LA, SA, SA+LA). Results: A total 
of 238 patients nonadherent to stimulants prior to initiating GXR were analyzed; 
38% were female, mean (SD) age was 10.3 (3.3) years, unadjusted pre- and post-
GXR stimulant MPR was 0.51 (0.16) and 0.82 (0.25), respectively, and the change 
in MPR was 0.31 (0.28). Among LA patients (n= 162), mean unadjusted pre-GXR 
stimulant MPR was 0.50, and 0.80 post-GXR; among SA and SA+LA patients (n= 76), 
this was 0.53 (pre-GXR) and 0.88 (post-GXR). The mean adjusted (i.e., post-model 
estimation) change in MPR was 0.29 (95% CI: 0.27-0.32) for LA patients versus 
0.34 (95% CI: 0.31-0.38) for combined SA and SA+LA patients (difference= 0.05; 
P= 0.013). cOnclusiOns: Among patients nonadherent to stimulant treatment, 
prior to initiating adjunctive GXR, adding GXR was associated with positive 
changes in stimulant adherence, with statistically significant differences in the 
